【24h】

Pseudomonas aeruginosa in French hospitals between 2001 and 2011: back to susceptibility

机译:2001年至2011年间法国医院中的铜绿假单胞菌:回到易感性

获取原文
获取原文并翻译 | 示例
       

摘要

The European Antimicrobial Resistance Surveillance Network (EARS-Net) reported an increase in the rates of resistance of Pseudomonas aeruginosa to antimicrobials between 2008 and 2011 in France. This alarming report was based on data collected during the harmonisation of breakpoints by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) committee. However, these data were not supported by the findings of other national surveillance networks. In this study, we assessed the trends in P. aeruginosa antimicrobial drug resistance at six French hospitals over a longer period of time (2001–2011) and with a constant definition of resistance. After the exclusion of incomplete data and duplicates, we sorted 34,065 isolates into the antimicrobial resistance patterns defined by the European Centre for Disease Prevention and Control (ECDC). The proportion of isolates with a resistant pattern (non-susceptible to one or two antimicrobial categories), a multidrug-resistant pattern (non-susceptible to three or four antimicrobial categories) or an extensively drug-resistant pattern (non-susceptible to five or six antimicrobial categories) decreased significantly over time. Logically, the proportion of isolates with a wild-type resistance pattern has increased significantly over the same period. No significant changes in the rates of resistance to cephalosporins and penicillins were observed, whereas carbapenem resistance rates increased. By contrast, the proportion of isolates resistant to fluoroquinolones, aminoglycosides and monobactams decreased significantly over time. In conclusion, our data do not confirm the EARS-net data, suggesting instead that antimicrobial drug resistance in P. aeruginosa might not have increased in French hospitals over the last decade.
机译:欧洲抗菌素耐药性监测网络(EARS-Net)报告称,法国的铜绿假单胞菌对抗菌素的耐药率在2008年至2011年期间有所增加。这份令人震惊的报告基于欧洲抗菌药物敏感性测试委员会(EUCAST)在协调断点期间收集的数据。但是,其他国家监视网络的调查结果不支持这些数据。在这项研究中,我们评估了法国的六家医院在较长时期(2001-2011年)中铜绿假单胞菌抗菌药物耐药性的趋势,并对耐药性进行了定义。排除不完整的数据和重复项后,我们将34,065株分离物归入了欧洲疾病预防控制中心(ECDC)定义的抗药性模式。具有抗药性模式(对一种或两种抗微生物类别不敏感),多药抗药性模式(对三种或四种抗微生物类别不敏感)或广泛耐药性模式(对五种或多种抗药性敏感)的分离株比例六个抗菌类别)随着时间的推移显着下降。从逻辑上讲,具有野生型抗性模式的分离株比例在同一时期已显着增加。观察到的对头孢菌素和青霉素的耐药率没有显着变化,而对碳青霉烯的耐药率却增加了。相反,随着时间的推移,对氟喹诺酮类,氨基糖苷类和单bactams耐药菌株的比例显着下降。总之,我们的数据不能确认EARS-net数据,这表明在过去的十年中,法国医院的铜绿假单胞菌的抗菌药物耐药性可能并未增加。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号